Privately held ARYx Therapeutics Inc. signed its first major partnership since its founding in 1998, granting to Procter & Gamble Pharmaceuticals Inc. worldwide development and commercialization rights to ATI-7505 in gastrointestinal disorders. (BioWorld Today)